Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proscar v. Cardura $50 mil. BPH disease progression comparative study begins enrollment at NIDDK.

Executive Summary

PROSCAR v. CARDURA NIDDK BPH PROGRESSION TRIAL BEGINS RECRUITMENT for a comparative study of Merck's 5-alpha-reductase inhibitor Proscar (finasteride) and Pfizer's alpha1 blocker Cardura (doxazosin) alone and in combination. The study of the progression of benign prostatic hyperplasia is being conducted under the auspices of the National Institute of Diabetes & Digestive & Kidney Diseases. It was first announced at a press conference on a 1,200-patient one-year BPH study at the Department of Veterans Affairs comparing Proscar with Abbott's Hytrin (terazosin), a combination of the two or placebo. The alpha blocker Hytrin outperformed Proscar in symptom improvement ("The Pink Sheet" Aug. 28, T&G-10).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026814

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel